Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 16/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | BPTF | Q12830 | 1/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.42 |
| ▸ | EEF2K | O00418 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 7/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30162299 | 1.00 | ACHE (0.46) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL21963472 | 0.85 | ACHE (0.41) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL22019783 | 0.81 | SMN1; SMN2 (0.40) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL24978541 | 0.80 | SMN1; SMN2 (0.39) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL21963238 | 0.78 | ACHE (0.42) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL22020383 | 0.78 | NLRP3 (0.44) | MAPK1NLRP3EEF2KSMN1; SMN2L3MBTL1 | |
| SCHEMBL21962951 | 0.77 | ACHE (0.52) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL30162391 | 0.77 | ACHE (0.52) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL21963214 | 0.77 | ACHE (0.52) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL22020326 | 0.76 | ACHE (0.50) | ACHEMEN1MAPK1KMT2ABPTF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
| WO-2020102096-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ACHE 4177/4885MEN1 3390/4885MAPK1 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.